ClinicalTrials.gg
CompletedNCT03454503Updated Feb 23, 2021

Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt

An observational study in Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase, sponsored by Hikma Pharmaceuticals LLC. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-23.

Primary conditionLeukemia, Myelogenous, Chronic, BCR-ABL PositiveRegistry: LeukemiaReclassifiedWhy we changed it
Registry
Leukemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Why
  1. The study's listed conditions name Leukemia, Myelogenous, Chronic, BCR-ABL Positive, a narrower term within Leukemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hikma Pharmaceuticals LLC · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
173
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this observational study is to evaluate the effectiveness and safety of generic imatinib under usual clinical practice in patients of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) patients in chronic phase (CP) in Egypt

Read the detailed description

An observational, multi-center, prospective cohort study to assess the effectiveness and safety of generic Imatinib (Carcemia®) in patients with Ph+ CML who are newly diagnosed or patients who will be switched from the reference product (Glivec® ) to Carcemia® where treatment will be prescribed by the investigator in accordance with clinical practice where no visits or intervention(s) additional to the daily practice will be performed.

Eligible Ph+ CML patients in both cohorts will be followed up for a total of 18 months.

02

Conditions studied

  • Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase

Browse trials for

Keywords

  • Imatinib
  • Generic Imatinib
  • Leukemia
  • Chronic myeloid leukemia
  • Philadelphia chromosome-positive
  • Chronic phase
  • Observational study
  • Switched patients
  • Tyrosine kinase inhibitor
03

In context

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Reclassified

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

This study's enrollment of 173 is above the median of 141 across 147 observational studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Lead sponsor

Hikma Pharmaceuticals LLC is the lead sponsor of 14 studies on the registry; 1 is open to participants now.

Compared within Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be recruited from 2 sites in Egypt

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

First cohort (newly diagnosed patients):

  • Age ≥18 years
  • Newly diagnosed patients with Ph+ CML in CP, with or without the presence of other cytogenetic abnormalities at the time of diagnosis
  • Treatment naïve patients with confirmed diagnosis within 3 months of study enrolment
  • Levels of liver aminotransferases and serum ≤ 2 times the , and serum creatinine ≤1.5 times the upper limit of the normal range
  • Written

Second cohort (switched patients):

  • Age ≥18 years
  • Ph+ CML patients in CP currently treated with Glivec®, with or without the presence of other cytogenetic abnormalities at the time of switch
  • Levels of liver aminotransferases and serum bilirubin ≤ 2 times the upper limit of the normal range and serum creatinine ≤1.5 times the upper limit of the normal range
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • CML in accelerated phase (AP) at enrollment except patients in AP with the presence of other cytogenetic abnormalities at the time of diagnosis
  • CML in BP at enrollment
  • Patients who meet any of the to the administration of the study drug according to the approved Summary of Product Characteristics
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
173 participants (actual)
Patient registry
No

Groups and cohorts

  • First cohort

    Newly diagnosed patients

    Drug: Imatinib

  • Second cohort

    Patients switched from reference product (Glivec® )

    Drug: Imatinib

Interventions

  • Film coated tablet contains 400 mg imatinib (as mesilate)

    Also known as: Carcemia®

06

What researchers measure

Primary outcomes

  1. Proportion of patients who achieve and maintain major molecular response (MMR)

    Major molecular response (MMR) is measured using real-time quantitative polymerase chain reaction (RQ-PCR) test and is defined as BCR-ABL1 ≤ 0.1%

    Time frame: 12 months

Secondary outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs) to generic Imatinib (Carcemia®)

    Number, type, severity and frequency of adverse events (AEs), serious AEs (SAEs), and clinically relevant changes in laboratory tests according to laboratory reference ranges

    Time frame: 18 months

  2. Progression free survival (PFS)

    Proportion of CML patients who will not experience disease progression from enrollment to 18 months study endpoint.

    Time frame: 18 months

  3. Event free survival (EFS)

    Proportion of CML patients who will not experience event from enrollment to 18 months study endpoint

    Time frame: 18 months

  4. Survival without blastic phase (BP)

    Proportion of CML patients who will not experience blastic phase (BP) from enrollment to 18 months study endpoint.

    Time frame: 18 months

  5. Overall survival (OS)

    Proportion of CML patients who will not die till 18 months study endpoint.

    Time frame: 18 months

  6. Complete cytogenetic response (CCgR)

    Proportion of CML patients who will achieve no Ph+ metaphases at 12 months study endpoint by conventional cytogenetics and/or FISH test.

    Time frame: 12 months

  7. Complete molecular response (CMR)

    Proportion of CML patients who will achieve undetectable BCR-ABL mRNA transcripts by RQ-PCR test in two consecutive blood samples of adequate quality.

    Time frame: 12 months

  8. Health-Related Quality of Life (HRQoL)

    Mean change in Health-Related Quality of Life (HRQoL) utilizing EORTC QOLCML24 questionnaire throughout treatment visits

    Time frame: 18 months

  9. Treatment compliance on generic Imatinib

    Evaluated by identifying the frequency of not taking the medications as prescribed and the reasons. The decision on non-compliance is based on the treating physician's judgment.

    Time frame: 18 months

07

Study locations

1 site
  • National Cancer Institute (NCI)
    Cairo, 11796, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Dec 2020, 31 months.

Of 67 observational studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2018
First posted
Mar 6, 2018
StartActual
May 13, 2018
Primary completionActual
Dec 28, 2020
CompletionActual
Dec 28, 2020
Last update
Feb 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03454503
Responsible party
Sponsor
First posted
Mar 6, 2018
Start date
May 13, 2018
Primary completion
Dec 28, 2020
Completion
Dec 28, 2020
Last update
Feb 23, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion